Details
Stereochemistry | ACHIRAL |
Molecular Formula | C11H9I3N2O4 |
Molecular Weight | 613.9136 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(=O)NC1=C(I)C(C(O)=O)=C(I)C(NC(C)=O)=C1I
InChI
InChIKey=YVPYQUNUQOZFHG-UHFFFAOYSA-N
InChI=1S/C11H9I3N2O4/c1-3(17)15-9-6(12)5(11(19)20)7(13)10(8(9)14)16-4(2)18/h1-2H3,(H,15,17)(H,16,18)(H,19,20)
DescriptionSources: http://www.drugbank.ca/drugs/DB00271Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/010040s171lbl.pdf
Sources: http://www.drugbank.ca/drugs/DB00271
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/010040s171lbl.pdf
This compound belongs to the class of organic compounds known as aminobenzoic acids. These are benzoic acids containing an amine group attached to the benzene moiety. A commonly used x-ray contrast medium. Used, alone or in combination, for a wide variety of diagnostic imaging methods, including angiography, urography, cholangiography, computed tomography, hysterosalpingography, and retrograde pyelography. It can be used for imaging the gastrointestinal tract in patients allergic to barium. Radiopaque agents are drugs used to help diagnose certain medical problems. They contain iodine, which blocks x-rays. Depending on how the radiopaque agent is given, it localizes or builds up in certain areas of the body. The resulting high level of iodine allows the x-rays to make a "picture" of the area. The areas of the body in which the radiopaque agent localizes will appear white on the x-ray film. This creates the needed distinction, or contrast, between one organ and other tissues.
CNS Activity
Originator
Sources: http://www.ncbi.nlm.nih.gov/pubmed/?term=3198373
Curator's Comment: Diatrizoic acid was discovered in 1953 simultaneously and independently by Schering AG in Berlin and by Sterling-Winthrop in the USA.
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Diagnostic | Cystografin Approved UseRetrograde cystourethrography Launch Date1955 |
|||
Diagnostic | Gastrografin Approved UseGastrografin (DIATRIZOIC ACID) is indicated for radiographic examination of segments of the gastrointestinal tract (esophagus, stomach, proximal small intestine, and colon). Launch Date1958 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
7 mg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6706519 |
7.2 mg/kg single, intravenous dose: 7.2 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
HYDROGEN IODIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
3.6 mg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6706519 |
3.36 mg/kg single, intravenous dose: 3.36 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
HYDROGEN IODIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
102 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6706519 |
7.2 mg/kg single, intravenous dose: 7.2 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
HYDROGEN IODIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
110 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6706519 |
3.36 mg/kg single, intravenous dose: 3.36 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
HYDROGEN IODIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
PubMed
Title | Date | PubMed |
---|---|---|
Transcervical catheterization and cervical patency during the oestrous cycle in domestic cats. | 2001 |
|
Preoperative bowel preparation with meglumine and sodium diatrizoate (Gastrografin): a prospective randomised comparison. | 2001 Dec |
|
Results after colectomy for colonic inertia: a sixteen-year experience. | 2001 Dec |
|
Flow-directed microcatheters for cerebral embolizations using Ethibloc--an in vitro study. | 2001 Dec |
|
Effects of radiographic contrast media on pulmonary vascular resistance of normoxic and chronically hypoxic pulmonary hypertensive rats. | 2001 Dec |
|
Radiographic contrast media induced nephropathy: experimental observations and the protective effect of calcium channel blockers. | 2001 Dec |
|
Re: Renal artery embolization with diluted hot contrast medium: an experimental study. | 2001 Dec |
|
Diagnostic accuracy of focused appendiceal CT in clinically equivocal cases of acute appendicitis. | 2001 Dec |
|
Rapid diagnosis of sigmoid volvulus with water soluble urografin in emergency service. | 2001 Nov |
|
Appendiceal disease in women with endometriosis and right lower quadrant pain. | 2001 Nov |
|
Videourodynamic and sphincter motor unit potential analyses in Parkinson's disease and multiple system atrophy. | 2001 Nov |
|
Differential effects of radiocontrast agents on human umbilical vein endothelial cells: cytotoxicity and modulators of thrombogenicity. | 2001 Nov 20 |
|
Pseudomembranous colitis without diarrhea presenting clinically as acute intestinal pseudo-obstruction. | 2001 Sep |
|
[Opportunities of delayed densitometry of "late (fixed) contrast" as a test for tumors in residual mediastinal lesion in primary mediastinal lymphosarcoma after polychemotherapy]. | 2002 |
|
Ionic radiocontrast media disrupt intercellular contacts via an extracellular calcium-independent mechanism. | 2002 |
|
[Which imaging in case of sigmoid diverticulitis? The value of ultrasound (Conventional B-mode in combination with hydrocolonsonography and colour flow Doppler) in comparison to the well-established modalities like contrast enema and helical computertomography]. | 2002 Apr |
|
Short-term moderate sodium restriction induces relative hyperfiltration in normotensive normoalbuminuric Type I diabetes mellitus. | 2002 Apr |
|
Diagnosis and management of enterovesical fistulas in patients with Crohn's disease. | 2002 Aug |
|
Electrocardiographic effects of diagnostic imaging agents. | 2002 Aug |
|
Application of oral contrast media in coregistered positron emission tomography-CT. | 2002 Aug |
|
Emergency colonoscopy for distal intestinal obstruction syndrome in cystic fibrosis patients. | 2002 Aug |
|
Thumbprinting due to ischemic colitis in a patient on oral anticoagulation. | 2002 Aug-Sep |
|
Use of near-infrared reflection spectroscopy to study the effects of X-ray contrast media on renal tolerance in rats: effects of a prostacyclin analogue and of phosphodiesterase inhibitors. | 2002 Dec |
|
Rectal washout with cytotoxic solution can be extended to the whole colon. | 2002 Dec |
|
Evidence for involvement of mast cell degranulation and subsequent stimulation of histamine H1 and H2 receptors in radiographic contrast media-increased vascular permeability in rats. | 2002 Dec |
|
Virtual gastroduodenoscopy: a new look at the bypassed stomach and duodenum after laparoscopic Roux-en-Y gastric bypass for morbid obesity. | 2002 Feb |
|
Systemic platelet effects of contrast media: implications for cardiologic research and clinical practice. | 2002 Jan |
|
Plasma exogenous creatinine clearance test in dogs: comparison with other methods and proposed limited sampling strategy. | 2002 Jan-Feb |
|
Effects of intrathecal injection of diatrizoate on dopamine receptors. | 2002 Jul |
|
Contrast radiography and intestinal obstruction. | 2002 Jul |
|
Therapeutic value of gastrografin in adhesive small bowel obstruction after unsuccessful conservative treatment: a prospective randomized trial. | 2002 Jul |
|
Local tissue toxicity in response to extravascular extravasation of magnetic resonance contrast media. | 2002 Jul |
|
Iodinated contrast medium-induced potassium release: the effect of mixing ratios. | 2002 Jul-Aug |
|
Type IV diaphragmatic hiatal hernia. | 2002 Jun-Jul |
|
Do clinically relevant circulating concentrations of radiographic contrast agents inhibit platelet-dependent arterial thrombosis? | 2002 Mar 1 |
|
[Ultrasound and X-ray urethrography and urethroscopy during endoscopic operations on the urethra]. | 2002 Mar-Apr |
|
A case of gastric duplication evaluated by gastric emptying scintigraphy. | 2002 May |
|
Long-term survival of patients with stage IV hypopharyngeal cancer: impact of fundus rotation gastroplasty. | 2002 May |
|
Safety and efficacy of postoperative continuous positive airway pressure to prevent pulmonary complications after Roux-en-Y gastric bypass. | 2002 May-Jun |
|
The role of theophylline in contrast-induced nephropathy: a case-control study. | 2002 Nov |
|
Pressure-assisted micturating cystourethrography: reduction in duration of procedure and fluoroscopy time. | 2002 Nov |
|
The value of contrast radiology for postoperative adhesive small bowel obstruction. | 2002 Nov-Dec |
|
Venous port salvage utilizing low dose tPA. | 2002 Nov-Dec |
|
Chronic renal dysfunction late after liver transplantation. | 2002 Oct |
|
Renal chemoembolization with mitomycin c/Ethibloc: pharmacokinetics and efficacy in an animal model. | 2002 Sep |
|
The diagnostic yield of colonoscopy and the therapeutic value of intraduodenal amidotrizoic acid injection in intestinal Diphyllobothrium latum infection: report of a case. | 2002 Sep |
|
Ex vivo expansion of megakaryocyte progenitors from cryopreserved umbilical cord blood. A potential source of megakaryocytes for transplantation. | 2002 Sep |
|
Is same-day sonography of the gallbladder feasible after intravenous urography or contrast-enhanced computed tomography? | 2002 Sep |
|
Iothalamate measured by capillary electrophoresis is a suitable alternative to radiolabeled inulin in renal micropuncture. | 2002 Sep |
|
[Fast method of labelling leukocytes with 99mTc HM PAO]. | 2002 Sep-Oct |
Sample Use Guides
In Vivo Use Guide
Curator's Comment: For radiographic examination of segments of the gastrointestinal tract (Gastrografin) oral administration: adult oral dosage may range from 30 to 90 mL (11 to 33 g iodine), depending on the nature of the examination and the size of the patient. For Enemas or Enterostomy Instillations: should be diluted when it is used for enemas and enterostomy instillations. When used as an enema, the suggested dilution for adults is 240 mL (88 g iodine) in 1,000 mL of tap water. http://www.drugs.com/pro/gastrografin.html
;
The dose for retrograde use in cystography and voiding cystourethrography ranges from 25 to 300 mL depending on the age of the patient and the degree of bladder irritability
Route of Administration:
Other
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C390
Created by
admin on Mon Mar 31 17:47:45 GMT 2025 , Edited by admin on Mon Mar 31 17:47:45 GMT 2025
|
||
|
NDF-RT |
N0000180185
Created by
admin on Mon Mar 31 17:47:45 GMT 2025 , Edited by admin on Mon Mar 31 17:47:45 GMT 2025
|
||
|
WHO-VATC |
QV08AA01
Created by
admin on Mon Mar 31 17:47:45 GMT 2025 , Edited by admin on Mon Mar 31 17:47:45 GMT 2025
|
||
|
WHO-ATC |
V08AA01
Created by
admin on Mon Mar 31 17:47:45 GMT 2025 , Edited by admin on Mon Mar 31 17:47:45 GMT 2025
|
||
|
NDF-RT |
N0000010258
Created by
admin on Mon Mar 31 17:47:45 GMT 2025 , Edited by admin on Mon Mar 31 17:47:45 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB00271
Created by
admin on Mon Mar 31 17:47:45 GMT 2025 , Edited by admin on Mon Mar 31 17:47:45 GMT 2025
|
PRIMARY | |||
|
m4263
Created by
admin on Mon Mar 31 17:47:45 GMT 2025 , Edited by admin on Mon Mar 31 17:47:45 GMT 2025
|
PRIMARY | Merck Index | ||
|
100000091574
Created by
admin on Mon Mar 31 17:47:45 GMT 2025 , Edited by admin on Mon Mar 31 17:47:45 GMT 2025
|
PRIMARY | |||
|
59733
Created by
admin on Mon Mar 31 17:47:45 GMT 2025 , Edited by admin on Mon Mar 31 17:47:45 GMT 2025
|
PRIMARY | |||
|
C016826
Created by
admin on Mon Mar 31 17:47:45 GMT 2025 , Edited by admin on Mon Mar 31 17:47:45 GMT 2025
|
PRIMARY | |||
|
C47483
Created by
admin on Mon Mar 31 17:47:45 GMT 2025 , Edited by admin on Mon Mar 31 17:47:45 GMT 2025
|
PRIMARY | |||
|
DTXSID0044521
Created by
admin on Mon Mar 31 17:47:45 GMT 2025 , Edited by admin on Mon Mar 31 17:47:45 GMT 2025
|
PRIMARY | |||
|
Diatrizoate
Created by
admin on Mon Mar 31 17:47:45 GMT 2025 , Edited by admin on Mon Mar 31 17:47:45 GMT 2025
|
PRIMARY | |||
|
4042
Created by
admin on Mon Mar 31 17:47:45 GMT 2025 , Edited by admin on Mon Mar 31 17:47:45 GMT 2025
|
PRIMARY | |||
|
1184005
Created by
admin on Mon Mar 31 17:47:45 GMT 2025 , Edited by admin on Mon Mar 31 17:47:45 GMT 2025
|
PRIMARY | |||
|
5UVC90J1LK
Created by
admin on Mon Mar 31 17:47:45 GMT 2025 , Edited by admin on Mon Mar 31 17:47:45 GMT 2025
|
PRIMARY | |||
|
DIATRIZOIC ACID
Created by
admin on Mon Mar 31 17:47:45 GMT 2025 , Edited by admin on Mon Mar 31 17:47:45 GMT 2025
|
PRIMARY | Description: A white or almost white, crystalline powder; odourless. Solubility: Very slightly soluble in water and ethanol (~750 g/l) TS; soluble in dimethylformamide R; sparingly soluble in methanol R; practically insoluble in ether R; dissolves in solutions of alkali hydroxides. Category: Used in the preparation of meglumine amidotrizoate as a radiocontrast medium. Storage: Amidotrizoic acid should be kept in a well-closed container, protected from light. Labelling: The designation on the container of amidotrizoic acid should state whether the substance is the dihydrate or the anhydrous form. Requirement: Amidotrizoic acid contains not less than 98.0% and not more than the equivalent of 102.0% of C11H9I3N2O4, calculated with reference to the dried substance. | ||
|
SUB00443MIG
Created by
admin on Mon Mar 31 17:47:45 GMT 2025 , Edited by admin on Mon Mar 31 17:47:45 GMT 2025
|
PRIMARY | |||
|
5UVC90J1LK
Created by
admin on Mon Mar 31 17:47:45 GMT 2025 , Edited by admin on Mon Mar 31 17:47:45 GMT 2025
|
PRIMARY | |||
|
117-96-4
Created by
admin on Mon Mar 31 17:47:45 GMT 2025 , Edited by admin on Mon Mar 31 17:47:45 GMT 2025
|
PRIMARY | |||
|
262168
Created by
admin on Mon Mar 31 17:47:45 GMT 2025 , Edited by admin on Mon Mar 31 17:47:45 GMT 2025
|
PRIMARY | |||
|
851
Created by
admin on Mon Mar 31 17:47:45 GMT 2025 , Edited by admin on Mon Mar 31 17:47:45 GMT 2025
|
PRIMARY | |||
|
1546223
Created by
admin on Mon Mar 31 17:47:45 GMT 2025 , Edited by admin on Mon Mar 31 17:47:45 GMT 2025
|
PRIMARY | |||
|
D003973
Created by
admin on Mon Mar 31 17:47:45 GMT 2025 , Edited by admin on Mon Mar 31 17:47:45 GMT 2025
|
PRIMARY | |||
|
DIATRIZOIC ACID
Created by
admin on Mon Mar 31 17:47:45 GMT 2025 , Edited by admin on Mon Mar 31 17:47:45 GMT 2025
|
PRIMARY | |||
|
2140
Created by
admin on Mon Mar 31 17:47:45 GMT 2025 , Edited by admin on Mon Mar 31 17:47:45 GMT 2025
|
PRIMARY | |||
|
CHEMBL1201220
Created by
admin on Mon Mar 31 17:47:45 GMT 2025 , Edited by admin on Mon Mar 31 17:47:45 GMT 2025
|
PRIMARY | |||
|
204-223-6
Created by
admin on Mon Mar 31 17:47:45 GMT 2025 , Edited by admin on Mon Mar 31 17:47:45 GMT 2025
|
PRIMARY | |||
|
3319
Created by
admin on Mon Mar 31 17:47:45 GMT 2025 , Edited by admin on Mon Mar 31 17:47:45 GMT 2025
|
ALTERNATIVE | |||
|
53691
Created by
admin on Mon Mar 31 17:47:45 GMT 2025 , Edited by admin on Mon Mar 31 17:47:45 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)